Search Results - "Hederer, Bettina"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial by Beasley, Richard W, Donohue, James F, Mehta, Rajendra, Nelson, Harold S, Clay, Michelle, Moton, Allen, Kim, Han-Joo, Hederer, Bettina M

    Published in BMJ open (03-02-2015)
    “…Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and…”
    Get full text
    Journal Article
  2. 2

    Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations by Beeh, Kai-Michael, Hederer, Bettina, Glaab, Thomas, Müller, Achim, Rutten-van Moelken, Maureen, Kesten, Steven, Vogelmeier, Claus

    “…Currently available long-acting inhaled bronchodilators (tiotropium, salmeterol, formoterol) have demonstrated beneficial effects on exacerbations in…”
    Get full text
    Journal Article
  3. 3

    Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD by Vogelmeier, Claus, Hederer, Bettina, Glaab, Thomas, Schmidt, Hendrik, Rutten-van Mölken, Maureen P.M.H, Beeh, Kai M, Rabe, Klaus F, Fabbri, Leonardo M

    Published in The New England journal of medicine (24-03-2011)
    “…An important goal in the treatment of COPD is the prevention of exacerbations. In this trial, the investigators found that treatment with tiotropium, as…”
    Get full text
    Journal Article
  4. 4

    Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers by Vaidya, Soniya, Ziegler, Dominik, Tanase, Ana-Maria, Malmqvist, Ulf, Kanniess, Frank, Hederer, Bettina, Hosoe, Motoi

    Published in Pulmonary pharmacology & therapeutics (01-10-2021)
    “…QMF149 is an inhaled fixed-dose combination of indacaterol acetate and mometasone furoate (MF) delivered via Breezhaler®, under development for once-daily…”
    Get full text
    Journal Article
  5. 5

    Potential systemic effects of acquired CFTR dysfunction in COPD by Miravitlles, Marc, Criner, Gerard J, Mall, Marcus A, Rowe, Steven M, Vogelmeier, Claus F, Hederer, Bettina, Schoenberger, Matthias, Altman, Pablo

    Published in Respiratory medicine (01-01-2024)
    “…Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation, respiratory symptoms, inflammation of the airways, and systemic…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique by Brand, Peter, Hederer, Bettina, Austen, George, Dewberry, Helen, Meyer, Thomas

    “…Aerosols delivered by Respimat Soft Mist Inhaler (SMI) are slower-moving and longer-lasting than those from pressurized metered-dose inhalers (pMDIs),…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Higher lung deposition with Respimat super(ARG) Soft Mist super(ac) Inhaler than HFA-MDI in COPD patients with poor technique by Brand, Peter, Hederer, Bettina, Austen, George, Dewberry, Helen, Meyer, Thomas

    “…Aerosols delivered by Respimat super(ARG) Soft Mist super(ac) Inhaler (SMI) are slower-moving and longer-lasting than those from pressurized metered-dose…”
    Get full text
    Journal Article
  10. 10

    Higher lung deposition with Respimat reg; Soft Mist trade; Inhaler than HFA-MDI in COPD patients with poor technique by Peter Brand, Bettina Hederer, George Austen, Helen Dewberry, Thomas Meyer

    “…Peter Brand1, Bettina Hederer2, George Austen3, Helen Dewberry3, Thomas Meyer41RWTH, Aachen, Germany; 2Boehringer Ingelheim, Ingelheim, Germany; 3Boehringer…”
    Get full text
    Journal Article